Abstract
The cellular electrophysiologic effect of GYKI 16638, a new antiarrhythmic compound was studied and compared with that of sotalol and mexiletine in undiseased human right ventricular muscle preparation by applying the conventional microelectrode technique. GYKI 16638 (5 μM), at stimulation cycle length of 1000 ms, lengthened action potential duration (APD90) from 338.9 ± 28.6 ms to 385.4 ± 24 ms (n = 9, p < 0.05). This APD lengthening effect, unlike that of sotalol (30 μM), was rate-independent. GYKI 16638, contrary to sotalol and like mexiletine (10 μM), exerted a use-dependent depression of the maximal rate of depolarization (Vmax) which amounted to 36.4 ± 11.7 percent at cycle length of 400 ms (n = 5, p p < 0.05) and was characterised with an offset kinetical time constant of 298.6 ± 70.2 ms. It was concluded that GYKI 16638 in human ventricular muscle shows combined Class IB and Class III antiarrhythmic properties, resembling the electrophysiological manifestation seen after chronic amiodarone treatment.
Keywords: Antiarrhythmic, Sotalol, Mexiletine
Current Medicinal Chemistry
Title: The Cellular Electrophysiologic Effect of A New Amiodarone Like Antiarrhythmic Drug GYKI 16638 in Undiseased Human Ventricular Muscle: Comparison With Sotalol And Mexiletine
Volume: 9 Issue: 1
Author(s): M. Opincariu, A. Varro, N. Iost, L. Virag, O. Hala, J. Szolnoki, J. Szecsi, G. Bogats, P. Szenohradszky, P. Matyus and J. Gy. Papp
Affiliation:
Keywords: Antiarrhythmic, Sotalol, Mexiletine
Abstract: The cellular electrophysiologic effect of GYKI 16638, a new antiarrhythmic compound was studied and compared with that of sotalol and mexiletine in undiseased human right ventricular muscle preparation by applying the conventional microelectrode technique. GYKI 16638 (5 μM), at stimulation cycle length of 1000 ms, lengthened action potential duration (APD90) from 338.9 ± 28.6 ms to 385.4 ± 24 ms (n = 9, p < 0.05). This APD lengthening effect, unlike that of sotalol (30 μM), was rate-independent. GYKI 16638, contrary to sotalol and like mexiletine (10 μM), exerted a use-dependent depression of the maximal rate of depolarization (Vmax) which amounted to 36.4 ± 11.7 percent at cycle length of 400 ms (n = 5, p p < 0.05) and was characterised with an offset kinetical time constant of 298.6 ± 70.2 ms. It was concluded that GYKI 16638 in human ventricular muscle shows combined Class IB and Class III antiarrhythmic properties, resembling the electrophysiological manifestation seen after chronic amiodarone treatment.
Export Options
About this article
Cite this article as:
Opincariu M., Varro A., Iost N., Virag L., Hala O., Szolnoki J., Szecsi J., Bogats G., Szenohradszky P., Matyus P. and Gy. Papp J., The Cellular Electrophysiologic Effect of A New Amiodarone Like Antiarrhythmic Drug GYKI 16638 in Undiseased Human Ventricular Muscle: Comparison With Sotalol And Mexiletine, Current Medicinal Chemistry 2002; 9 (1) . https://dx.doi.org/10.2174/0929867023371517
DOI https://dx.doi.org/10.2174/0929867023371517 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ligand-Based Approaches in Virtual Screening
Current Computer-Aided Drug Design Administration of Exogenous Surfactant and Cytosolic Phospholipase A2α Inhibitors may Help COVID-19 Infected Patients with Chronic Diseases
Coronaviruses Pharmacologic Treatment for Prehypertension: To Treat or Not to Treat?
Recent Patents on Cardiovascular Drug Discovery Real-Time Location, Position and Motion Data for Healthcare Information Systems – A Patent Review
Recent Advances in Communications and Networking Technology (Discontinued) Predictors of “Worsening Renal Function” in Patients Hospitalized in Internal Medicine Department
Current Drug Safety EarlyVascularAgeing and Hypertension -A New Model for Understanding Cardiovascular Risk
Current Hypertension Reviews The Etiology of Hypertension in the Metabolic Syndrome Part Two: The Gene-Environment Interaction
Current Vascular Pharmacology Preventive and Therapeutic Role of Muscle Contraction Against Chronic Diseases
Current Pharmaceutical Design Nebivolol: More Than a Highly Selective Beta Blocker
Recent Patents on Cardiovascular Drug Discovery Staged Starnes Operation Preserving Patent Ductus Arteriosus for Neonates with Ebsteins Anomaly and Pulmonary Atresia
Current Cardiology Reviews Modulation of Cellular Mg2+ Content in Cardiac Cells by α1-Adrenoceptor Stimulation and Anti-Arrhythmic Agents
Recent Patents on Biotechnology Intrinsic Disorder in Male Sex Determination: Disorderedness of Proteins from the Sry Transcriptional Network
Current Protein & Peptide Science Potential Treatment of Cardiac Hypertrophy and Heart Failure by Inhibiting the Sarcolemmal Binding of Phospholipase Cβ1b
Current Drug Targets Current Experimental, Bioinformatic and Statistical Methods used in NMR Based Metabolomics
Current Metabolomics Myocardial Quantitative Analysis in Physiological and Pathological Ventricular Hypertrophy: The Increasing Role of Doppler Myocardial Imaging
Current Cardiology Reviews The Chemistry and Pharmacology of Genistein
The Natural Products Journal Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design Reduction of Sympathetic Hyperactivity by Agents that Inhibit the Renin Angiotensin Aldosterone System
Current Hypertension Reviews Pharmacological Manipulation of Brain Glycogenolysis as a Therapeutic Approach to Cerebral Ischemia
Mini-Reviews in Medicinal Chemistry Flavonoid Derivatives Targeting BCR-ABL Kinase: Semisynthesis, Molecular Dynamic Simulations and Enzymatic Inhibition
Current Topics in Medicinal Chemistry